Inhibition of HMOX1 has been demonstrated to increase the efficacy of chemotherapeutic agents, such as doxorubicin in breast cancer and temozolomide (TMZ) in melanoma, enhancing their therapeutic impact12. This evidence concerns the gene HMOX1 and breast cancer.